GEXVal Inc. is an R&D-focused drug discovery company founded in 2018 with a mission to develop pioneering solutions for rare and incurable diseases. The company's dedication to providing innovative and cost-effective treatment options in the Health Care industry sets it apart. GEXVal's recent ¥450.00M Series C investment on 04 December 2023 saw participation from notable investors including Mitsubishi UFJ Capital, SMBC Venture Capital, Axil Capital, UTC 2019 BioVentureFund, and Oita Venture Capital. This latest investment underscores confidence in GEXVal's commitment to improving lives through groundbreaking treatments, further solidifying its position as an innovative leader in the field.
GEXVal Inc.
Pioneering solutions to improve lives through innovative treatments for rare and incurable diseases.
Founded 2018
5 employees
Series C
Total: $1.56B
Health Care
General Information
Company Name
GEXVal Inc.
Founded Year
2018
Employees
5
Industries
Health Care
Funding Stage
Series C
BounceWatch is an independent company data service, not affiliated with GEXVal Inc.. To contact GEXVal Inc., visit gexval.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does GEXVal Inc. compare?
A PDF of GEXVal Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting GEXVal Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About GEXVal Inc.
Business keywords: R&D-focused, drug discovery, treatments, rare diseases, incurable diseases, quality of life, cost-effective treatments
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | ¥450.00M | 5 |
|
04 Dec 2023 |
| Series B | ¥700.00M | 5 |
|
10 Sep 2021 |
| Series A | ¥410.00M | - |
|
17 Jul 2018 |
GEXVal Inc. Alternatives & Competitors
View All Alternatives
GEXVal Inc. vs
Pioneering therapies that target rare neuroendocrine tumors and endocrine diseases for a brighter, h...
Series A
Biotechnology, Health Care
GEXVal Inc. vs
HemoShear Therapeutics
United States
Developing new treatments for rare metabolic disorders
Debt Financing
27 employees
Biotechnology, Health Care
GEXVal Inc. vs
Hansa Biopharma
Sweden
We are dedicated to bring innovative treatments to people living with rare immunological diseases.
Post-IPO Equity
144 employees
Biotechnology, Health Care
FAQ About GEXVal Inc.
Pioneering solutions to improve lives through innovative treatments for rare and incurable diseases.
GEXVal Inc. was founded in 2018.
GEXVal Inc. operates in Health Care. Its work centres on R&D-focused, drug discovery, treatments and rare diseases.
GEXVal Inc. has approximately 5 employees.
GEXVal Inc. has completed 3 funding rounds, raising a total of $1.56B. The latest funding stage is Series C.
Top alternatives and competitors to GEXVal Inc. include Tiburio Therapeutics, HemoShear Therapeutics, Hansa Biopharma, Dualyx, Healx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GEXVal Inc. and Tiburio Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for GEXVal Inc., https://bouncewatch.com/company/gexval, updated 14 January 2025. When citing, please name BounceWatch and link this page.
